Covid_19. Use this code when COVID-19 has been confirmed by laboratory testing irrespective of severity of clinical signs or symptoms. Use additional code, if desired, to identify pneumonia or other manifestations
Conditions
Interventions
Intervention 1: Intervention group:50 mg zinc tablets as a single dose made by Alhawi company for 14 days daily with lunch. Intervention 2: Control group: Placebo tablets, 14 days, with lunch, slaught
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Diagnosis of COVID-19 infection is subject to the approval of a specialist Age 18 to 65 years
Exclusion criteria
Exclusion criteria: addict Allergy to zinc Pregnancy and lactation Occurrence of special medical conditions History of AIDS and chronic lung disease History of corticosteroids and chemotherapy drugs in the past month Use of drugs that affect metabolism Use multivitamin supplements that are more than 10 mg per day
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level CRP. Timepoint: Measurement of reaction level _ thirty before the intervention and 14 days after starting zinc supplementation. Method of measurement: Enzyme-dependent immunosorbent assay kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Level of neutrophil to lymphocyte ratio. Timepoint: Measurement of neutrophil to lymphocyte ratio level before intervention and 14 days after zinc supplementation. Method of measurement: Microscopic counting. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Seyedeh Zahra Lotfi
Mashhad University of Medical Sciences
Outcome results
None listed